Sverre Sandberg Selected Research

Hydroxymethylbilane Synthase (Porphobilinogen Deaminase)

1/2021	Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.
1/2021	Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
1/2020	A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.
11/2019	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.
8/2013	Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria.
1/2004	Haplotype analysis of Norwegian and Swedish patients with acute intermittent porphyria (AIP): Extreme haplotype heterogeneity for the mutation R116W.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sverre Sandberg Research Topics

Disease

11	Acute Intermittent Porphyria (Porphyria, Acute) 01/2021 - 01/2004
4	Neoplasms (Cancer) 01/2022 - 01/2018
4	Diabetes Mellitus 01/2020 - 07/2005
4	Porphyrias (Porphyria) 04/2014 - 02/2011
3	Infections 01/2022 - 01/2018
3	Porphyria Cutanea Tarda 01/2022 - 04/2009
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2009
3	Metabolic Diseases (Metabolic Disease) 01/2021 - 02/2011
3	Type 2 Diabetes Mellitus (MODY) 01/2020 - 08/2010
3	Venous Thromboembolism 11/2017 - 11/2012
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2017 - 01/2009
2	COVID-19 08/2021 - 01/2020
2	Coronary Disease (Coronary Heart Disease) 01/2021 - 04/2019
2	Renal Insufficiency (Renal Failure) 01/2021 - 01/2020
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2020 - 04/2014
2	Prostatic Neoplasms (Prostate Cancer) 11/2018 - 11/2004
2	Inflammation (Inflammations) 01/2018 - 09/2012
2	Activated Protein C Resistance (APC Resistance) 01/2017 - 08/2010
2	Albuminuria 01/2017 - 05/2011
2	Myocardial Infarction 06/2014 - 07/2010
1	Skin Diseases (Skin Disease) 01/2022
1	Thyroid Diseases (Thyroid Disease) 01/2022
1	Iron Overload 01/2022
1	Homocystinuria 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Acute Coronary Syndrome 01/2020
1	Hereditary Coproporphyria (Coproporphyrinogen Oxidase Deficiency) 11/2019
1	Hepatic Porphyrias (Hepatic Porphyria) 11/2019
1	Variegate Porphyria (Protoporphyrinogen Oxidase Deficiency) 11/2019
1	Hemolysis 10/2019
1	Paresis (Hemiparesis) 07/2019
1	Pain (Aches) 07/2019
1	Respiratory Insufficiency (Respiratory Failure) 07/2019
1	Stroke (Strokes) 04/2019
1	Anemia 01/2018
1	Wounds and Injuries (Trauma) 01/2018
1	Pyelonephritis 09/2017
1	Thrombophilia 01/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 12/2016
1	Heart Diseases (Heart Disease) 12/2015
1	Diabetes Complications 12/2015
1	Foot Ulcer 12/2015
1	Thromboembolism 05/2015
1	Liver Diseases (Liver Disease) 10/2013

Drug/Important Bio-Agent (IBA)

10	Biological ProductsIBA 01/2022 - 04/2006
6	EnzymesIBA 01/2022 - 02/2011
6	Hydroxymethylbilane Synthase (Porphobilinogen Deaminase)IBA 01/2021 - 01/2004
5	Heme (Haem)IBA 01/2021 - 02/2011
4	TroponinIBA 01/2020 - 07/2010
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020 - 07/2005
3	Uroporphyrinogen Decarboxylase (Uroporphyrinogen III Decarboxylase)IBA 01/2022 - 04/2009
3	Hemoglobins (Hemoglobin)IBA 01/2020 - 12/2013
3	Pharmaceutical PreparationsIBA 01/2019 - 08/2010
3	fibrin fragment D (D-dimer)IBA 11/2017 - 11/2012
3	PorphobilinogenIBA 12/2008 - 04/2006
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2012
2	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 01/2022
2	Immunoglobulin G (IgG)IBA 08/2021 - 01/2020
2	Insulin (Novolin)FDA Link 01/2021 - 01/2009
2	PorphyrinsIBA 01/2020 - 11/2011
2	trans-crotonin (CTN)IBA 01/2020 - 12/2016
2	Acute Hepatic PorphyriaIBA 01/2020 - 09/2013
2	Glucose (Dextrose)FDA LinkGeneric 12/2015 - 09/2011
2	Warfarin (Coumadin)FDA LinkGeneric 05/2015 - 10/2006
2	AlbuminsIBA 05/2011 - 01/2009
2	Blood Glucose (Blood Sugar)IBA 01/2009 - 07/2005
1	Carcinoembryonic AntigenIBA 01/2022
1	insulin receptor-related receptor (IRR)IBA 01/2022
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	CA-125 Antigen (CA 125 Antigen)IBA 01/2022
1	Keratin-19 (Keratin 19)IBA 01/2022
1	HomocysteineIBA 01/2021
1	heme arginateIBA 01/2021
1	Methionine (L-Methionine)FDA Link 01/2021
1	givosiranIBA 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	AntibodiesIBA 01/2020
1	Lipoprotein(a)IBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	Coproporphyrinogen Oxidase (Coproporphyrinogen III Oxidases)IBA 11/2019
1	Protoporphyrinogen Oxidase (Protox)IBA 11/2019
1	Alkaline PhosphataseIBA 10/2019
1	Creatine Kinase (Creatine Phosphokinase)IBA 10/2019
1	BilirubinIBA 10/2019
1	ElectrolytesIBA 07/2019
1	hydroxymethylbilaneIBA 07/2019
1	Prostate-Specific Antigen (Semenogelase)IBA 11/2018
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 09/2017
1	Protein SIBA 01/2017
1	AntithrombinsIBA 01/2017
1	Factor V (Coagulation Factor V)IBA 01/2017
1	Protein CIBA 01/2017
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2017
1	Angiotensin Receptor AntagonistsIBA 01/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2013

Therapy/Procedure

4	Therapeutics 01/2021 - 01/2009
2	Glycemic Control 01/2020 - 01/2017
1	Secondary Prevention 04/2019